Forefront Analytics’s Provention Bio PRVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-14,997
Closed -$68K – 81
2022
Q3
$68K Sell
14,997
-6,430
-30% -$29.3K 0.04% 59
2022
Q2
$84K Sell
21,427
-1,175
-5% -$5.57K 0.04% 52
2022
Q1
$166K Buy
22,602
+900
+4% +$5.38K 0.06% 56
2021
Q4
$123K Buy
21,702
+600
+3% +$3.81K 0.04% 55
2021
Q3
$135K Buy
+21,102
New +$136K 0.05% 57

Other funds holding PRVB

Forefront Analytics's PRVB Position: Q4 2022 in Review

Forefront Analytics sold out of Provention Bio (PRVB) in Q4 2022, closing a stake of 14,997 shares — an estimated $68K sold.

Forefront Analytics first reported a position in PRVB in Q3 2021 and held it in 5 quarters. The position peaked at $166K in Q1 2022. 132 funds tracked by Wall St. Rank hold PRVB as of Q4 2022.

  • Forefront Analytics reported no remaining Provention Bio position as of Q4 2022 after selling out during the quarter.
  • Forefront Analytics sold 14,997 Provention Bio shares in Q4 2022, an estimated $68K.
  • Forefront Analytics first reported a position in Provention Bio in Q3 2021 and held it in 5 quarters.
  • Forefront Analytics's Provention Bio position peaked at $166K in Q1 2022.
  • 132 funds tracked by Wall St. Rank held Provention Bio as of Q4 2022.

Based on Forefront Analytics's 13F filing for Q4 2022, filed 13 Feb 2023.